Patents by Inventor Zahra Shahrokh

Zahra Shahrokh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STABLE FORMULATIONS FOR CNS DELIVERY OF ARYLSULFATASE A
    Publication number: 20140377244
    Abstract: The present invention provides, among oilier things, compositions and methods for CNS delivery of lysosomal enzymes (e.g., recombinant human arylsulfatase A (rhASA)) for effective treatment of lysosomal storage diseases (e.g. Metachromatic Leukodystrophy Disease). In some embodiments, the present invention includes a stable formulation for intrathecal administration comprising an ASA protein and a poloxamer, wherein less than 3% of the ASA protein exists in aggregated form.
    Type: Application
    Filed: December 21, 2012
    Publication date: December 25, 2014
    Inventors: Nazila Salamat-Miller, Katherine Taylor, Paul Campolieto, Zahra Shahrokh, Jing Pan, Lawrence Charnas, Teresa Leah Wright, Pericles Calias, Keethkumar Jain, Sujit Basu
  • METHODS AND COMPOSITIONS FOR CNS DELIVERY OF IDURONATE-2-SULFATASE
    Publication number: 20140271598
    Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an iduronate-2-sulfatase (I2S) protein, salt, and a polysorbate surfactant for the treatment of Hunters Syndrome.
    Type: Application
    Filed: August 23, 2013
    Publication date: September 18, 2014
    Applicant: Shire Human Genetic Therapies, Inc.
    Inventors: Gaozhong Zhu, Kris Lowe, Zahra Shahrokh, James Christian, Rick Fahrner, Jing Pan, Teresa Leah Wright, Pericles Calias
  • STABILIZED COMPOSITIONS OF PROTEINS HAVING A FREE THIOL MOIETY
    Publication number: 20140219987
    Abstract: Compositions of proteins having free thiols, and methods of making and using such compositions, are described.
    Type: Application
    Filed: September 6, 2013
    Publication date: August 7, 2014
    Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Gaozhong Zhu, Vinh Nguyen, Kris Lowe, Zahra Shahrokh
  • Stabilized compositions of proteins having a free thiol moeity
    Patent number: 8673298
    Abstract: Compositions of proteins having free thiols, and methods of making and using such compositions, are described.
    Type: Grant
    Filed: October 12, 2010
    Date of Patent: March 18, 2014
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Gaozhong Zhu, Vinh T. Nguyen, Kris Lowe, Zahra Shahrokh
  • Methods of binding TNF-? using anti-TNF-? antibody fragment-polymer conjugates
    Patent number: 8652468
    Abstract: Described are conjugates formed by an antibody fragment covalently attached to a nonproteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-? (TNF-?), human tissue factor (TF), human ?4?7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor ?-chain (TAC) for diagnostic and therapeutic applications.
    Type: Grant
    Filed: February 13, 2012
    Date of Patent: February 18, 2014
    Assignee: Genentech, Inc.
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Zahra Shahrokh, Gerardo Zapata
  • SUBCUTANEOUS ADMINISTRATION OF ALPHA-GALACTOSIDASE A
    Publication number: 20140037612
    Abstract: The invention relates, in part, to improved methods of administering ?-galactosidase A for the treatment of ?-galactosidase A deficiencies including Fabry disease.
    Type: Application
    Filed: May 24, 2013
    Publication date: February 6, 2014
    Applicant: Shire Human Genetic Therapies Inc.
    Inventors: Lisa Marie Sturk, Justin C. Lamsa, Michael W. Heartlein, Vinh Nguyen, Katherine D. Taylor, Zahra Shahrokh
  • METHODS AND COMPOSITIONS FOR CNS DELIVERY OF B-GALACTOCEREBROSIDASE
    Publication number: 20130295071
    Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an B-Galactocerebrosidase protein, salt, and a polysorbate surfactant for the treatment of GLD Disease.
    Type: Application
    Filed: April 12, 2013
    Publication date: November 7, 2013
    Inventors: Nazila Salamat-Miller, Katherine Taylor, Ken Manning, Gaozhong Zhu, Paul Campolieto, Zahra Shahrokh, Pericles Calias, Thomas McCauley
  • Methods and compositions for CNS delivery of iduronate-2-sulfatase
    Patent number: 8545837
    Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an iduronate-2-sulfatase (I2S) protein, salt, and a polysorbate surfactant for the treatment of Hunters Syndrome.
    Type: Grant
    Filed: June 25, 2011
    Date of Patent: October 1, 2013
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Gaozhong Zhu, Kris Lowe, Zahra Shahrokh, James Christian, Richard Fahmer, Jing Pan, Teresa Leah Wright, Pericles Calias
  • Apo-2 ligand/trail formulations
    Patent number: 8470969
    Abstract: The present invention relates generally to Apo2L/TRAIL purification involving crystallization.
    Type: Grant
    Filed: June 23, 2010
    Date of Patent: June 25, 2013
    Assignee: Genentech, Inc.
    Inventors: Heather Flores, Tanya P. Lin, Timothy C. Matthews, Roger Pai, Zahra Shahrokh, Evan E. Shave, Patricia A. Rancatore
  • Methods of binding TNF-alpha using Anti-TNF-alpha antibody fragment-polymer conjugates
    Publication number: 20130084302
    Abstract: Described are conjugates formed by an antibody fragment covalently attached to a nonproteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-? (TNF-?), human tissue factor (TF), human ?4?7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor ?-chain (TAC) for diagnostic and therapeutic applications.
    Type: Application
    Filed: February 13, 2012
    Publication date: April 4, 2013
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Zahra Shahrokh, Gerardo Zapata
  • Antibody fragment-polymer conjugates and uses of same
    Patent number: 8147830
    Abstract: Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-? (TNF-?), human tissue factor (TF), human ?4?7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor ?-chain (TAC) for diagnostic and therapeutic applications.
    Type: Grant
    Filed: August 4, 2010
    Date of Patent: April 3, 2012
    Assignee: Genentech, Inc.
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Zahra Shahrokh, Gerardo Zapata
  • Methods for making Apo-2 Ligand using divalent metal ions
    Publication number: 20120077740
    Abstract: Methods of making Apo-2 ligand and formulations of Apo-2 ligand using divalent metal ions are provided. Such divalent metal ions include zinc and cobalt which improve Apo-2 ligand trimer formation and stability. The crystal structure of Apo-2 ligand is also provided, along with Apo-2 ligand variant polypeptides identified using oligonucleotide-directed mutagenesis.
    Type: Application
    Filed: December 10, 2010
    Publication date: March 29, 2012
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Sarah Hymowitz, Robert F. Kelley, Iphigenia Koumenis, Woon-Lam Susan Leung, Mark O'Connell, Roger Pai, Zahra Shahrokh, Laura Simmons
  • METHODS AND COMPOSITIONS FOR CNS DELIVERY OF HEPARAN N-SULFATASE
    Publication number: 20120014936
    Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising a heparan N-sulfatase (HNS) protein, salt, and a polysorbate surfactant for the treatment of Sanfilippo Syndrome Type A.
    Type: Application
    Filed: June 25, 2011
    Publication date: January 19, 2012
    Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Farah Natoli, Gaozhong Zhu, Jennifer Terew, Yuan Jiang, Jamie Tsung, Zahra Shahrokh, Brian Vernaglia, Jing Pan, Richard Pfeifer, Pericles Calias
  • METHODS AND COMPOSITIONS FOR CNS DELIVERY OF ARYLSULFATASE A
    Publication number: 20120009171
    Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an arylsulfatase A (ASA) protein, salt, and a polysorbate surfactant for the treatment of Metachromatic Leukodystrophy Disease.
    Type: Application
    Filed: June 25, 2011
    Publication date: January 12, 2012
    Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Nazila Salamat-Miller, Katherine Taylor, Paul Campolieto, Zahra Shahrokh, Jing Pan, Lawrence Charnas, Teresa Leah Wright, Pericles Calias
  • CNS DELIVERY OF THERAPEUTIC AGENTS
    Publication number: 20120003202
    Abstract: The present invention provides an effective and less invasive approach for direct delivery of therapeutic agents to the central nervous system (CNS). In some embodiments, the present invention provides methods including a step of administering intrathecally to a subject suffering from or susceptible to a lysosomal storage disease associated with reduced level or activity of a lysosomal enzyme, a composition comprising a replacement enzyme for the lysosomal enzyme.
    Type: Application
    Filed: June 25, 2011
    Publication date: January 5, 2012
    Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Pericles Calias, Jing Pan, Jan Powell, Lawrence Charnas, Thomas McCauley, Teresa Leah Wright, Richard Pfeifer, Zahra Shahrokh
  • METHODS AND COMPOSITIONS FOR CNS DELIVERY OF IDURONATE-2-SULFATASE
    Publication number: 20110318323
    Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an iduronate-2-sulfatase (I2S) protein, salt, and a polysorbate surfactant for the treatment of Hunters Syndrome.
    Type: Application
    Filed: June 25, 2011
    Publication date: December 29, 2011
    Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Gaozhong Zhu, Kris Lowe, Zahra Shahrokh, James Christian, Rick Richard Fahmer, Jing Pan, Teresa Leah Wright, Pericles Calias
  • METHODS AND COMPOSITIONS FOR CNS DELIVERY OF B-GALACTOCEREBROSIDASE
    Publication number: 20110318324
    Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an B-Galactocerebrosidase protein, salt, and a polysorbate surfactant for the treatment of GLD Disease.
    Type: Application
    Filed: June 25, 2011
    Publication date: December 29, 2011
    Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Nazila Salamat-Miller, Katherine Taylor, Ken Manning, Gaozhong Zhu, Paul Campolieto, Zahra Shahrokh, Pericles Calias, Thomas McCauley
  • APO-2 LIGAND/TRAIL FORMULATIONS
    Publication number: 20110269947
    Abstract: The present invention relates generally to Apo2L/TRAIL purification involving crystallization.
    Type: Application
    Filed: June 23, 2010
    Publication date: November 3, 2011
    Inventors: Heather Flores, Tanya P. Lin, Timothy C. Matthews, Roger Pai, Zahra Shahrokh, Evan E. Shave, Patricia A. Rancatore
  • APO-2 ligand/trail formulations
    Publication number: 20110245185
    Abstract: The inventions include Apo2L/TRAIL formulations and methods of using such formulations. Lyophilized and crystal formulations of Apo-2L/TRAIL which are stable and have improved Apo2L/TRAIL trimer formation are provided. Methods of making Apo-2L/TRAIL formulations, as well as devices and kits containing such formulations are also provided.
    Type: Application
    Filed: October 21, 2010
    Publication date: October 6, 2011
    Applicant: Genentech, Inc.
    Inventors: Heather Flores, Tanya P. Lin, Timothy C. Matthews, Roger Pai, Zahra Shahrokh
  • ANTIBODY FRAGMENT-POLYMER CONJUGATES AND USES OF SAME
    Publication number: 20110104185
    Abstract: Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-? (TNF-?), human tissue factor (TF), human ?4?7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor ?-chain (TAC) for diagnostic and therapeutic applications.
    Type: Application
    Filed: August 4, 2010
    Publication date: May 5, 2011
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Zahra Shahrokh, Gerardo Zapata